Brandywine Global Investment Management LLC Sells 715 Shares of Heron Therapeutics Inc (HRTX)

Brandywine Global Investment Management LLC reduced its position in shares of Heron Therapeutics Inc (NASDAQ:HRTX) by 2.6% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 26,493 shares of the biotechnology company’s stock after selling 715 shares during the quarter. Brandywine Global Investment Management LLC’s holdings in Heron Therapeutics were worth $688,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently made changes to their positions in HRTX. Mackay Shields LLC raised its stake in Heron Therapeutics by 7.0% in the 4th quarter. Mackay Shields LLC now owns 23,975 shares of the biotechnology company’s stock valued at $622,000 after acquiring an additional 1,575 shares during the period. Geode Capital Management LLC raised its stake in Heron Therapeutics by 3.6% in the 4th quarter. Geode Capital Management LLC now owns 751,250 shares of the biotechnology company’s stock valued at $19,487,000 after acquiring an additional 26,429 shares during the period. Dimensional Fund Advisors LP bought a new stake in Heron Therapeutics in the 4th quarter valued at $450,000. Emory University raised its stake in Heron Therapeutics by 20.7% in the 4th quarter. Emory University now owns 84,265 shares of the biotechnology company’s stock valued at $2,186,000 after acquiring an additional 14,425 shares during the period. Finally, Royce & Associates LP raised its stake in Heron Therapeutics by 7.7% in the 4th quarter. Royce & Associates LP now owns 70,000 shares of the biotechnology company’s stock valued at $1,816,000 after acquiring an additional 5,000 shares during the period.

HRTX stock opened at $23.78 on Monday. Heron Therapeutics Inc has a fifty-two week low of $21.25 and a fifty-two week high of $42.90.

Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings data on Friday, February 22nd. The biotechnology company reported ($0.63) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.17). The firm had revenue of $28.84 million for the quarter, compared to the consensus estimate of $28.05 million. Heron Therapeutics had a negative return on equity of 54.98% and a negative net margin of 230.84%. Equities research analysts anticipate that Heron Therapeutics Inc will post -1.52 earnings per share for the current year.

HRTX has been the topic of a number of research analyst reports. Cantor Fitzgerald restated a “buy” rating and issued a $50.00 price target on shares of Heron Therapeutics in a research note on Monday, December 31st. Stifel Nicolaus restated a “buy” rating and issued a $54.00 price target on shares of Heron Therapeutics in a research note on Friday, February 22nd. Needham & Company LLC restated a “buy” rating and issued a $64.00 price target (down previously from $66.00) on shares of Heron Therapeutics in a research note on Wednesday, January 16th. BidaskClub upgraded Heron Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 20th. Finally, ValuEngine upgraded Heron Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday, February 4th. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have issued a buy rating to the stock. Heron Therapeutics currently has an average rating of “Buy” and an average target price of $51.82.

COPYRIGHT VIOLATION NOTICE: This story was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another website, it was illegally copied and republished in violation of US and international copyright and trademark laws. The original version of this story can be accessed at https://sportsperspectives.com/2019/03/25/brandywine-global-investment-management-llc-sells-715-shares-of-heron-therapeutics-inc-hrtx.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a biotechnology company, engages in developing medicines to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Recommended Story: Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).

Institutional Ownership by Quarter for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.